Live Analyst Rating Changes 24955 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Anderson Schock
BR

Anderson Schock

B. Riley Securities
Wall Street Analyst
★★★★☆
#398
on 13Foresight · ranked by our own returns
67%
Success Rate
+17.2%
Average Return
14 of 21 calls profitable · +9.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 67% of Anderson Schock's ratings turned a profit when each position was held for 1 year — averaging +17.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

29 Buy 3 Hold 0 Sell
Anderson's Stock Coverage 15 ratings · 2026-08-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
VREX
Varex Imaging
 Aug 10, 2026 HOLD Hold
+8.6% avg upside
9 analysts
$18.90
2.13% Upside
 +0.2% ·
LFMD
LifeMD
 Aug 06, 2026 BUY Strong Buy
+199.2% avg upside
14 analysts
$8.00
131.24% Upside
 +1.5% ·
XGN
Exagen
 Aug 05, 2026 BUY Strong Buy
+92.2% avg upside
10 analysts
$12.00
82.35% Upside
 +0.1% ·
INFU
InfuSystem Holdings
 Aug 05, 2026 BUY Strong Buy
+28.5% avg upside
7 analysts
$20.00
60.17% Upside
 +1.0% ·
ANIK
Anika Therapeutics
 Jul 30, 2026 BUY Strong Buy
+3.9% avg upside
4 analysts
$21.00
0.83% Downside
 +21.9% ·
NUTX
Clinigence Holdings
 Jun 26, 2026 BUY Strong Buy
+23.9% avg upside
5 analysts
$290.00
55.29% Upside
 +12.6% ·
CLPT
ClearPoint Neuro
 Jun 17, 2026 BUY Strong Buy
+42.9% avg upside
7 analysts
$30.00
94.45% Upside
 -8.7% ·
OBIO
Orchestra BioMed Holdings
 May 18, 2026 BUY Strong Buy
+200.6% avg upside
9 analysts
$10.00
124.75% Upside
 +10.8% ·
ELMD
Electromed
 May 13, 2026 BUY Strong Buy
-23.8% avg upside
6 analysts
$40.00
5.99% Downside
 +24.6% ·
OPRX
OptimizeRx
 May 13, 2026 BUY Strong Buy
+44.4% avg upside
9 analysts
$10.00
13.89% Upside
 +77.2% ·
TCMD
Tactile Systems Technology
 May 07, 2026 BUY Strong Buy
+72.2% avg upside
8 analysts
$36.00
51.84% Upside
 -7.0% ·
BEAT
HeartBeam
 Mar 31, 2026 BUY Buy
+548.6% avg upside
14 analysts
$4.00
578.14% Upside
 -53.3% ·
SPOK
Spok Holdings
 Feb 26, 2026 HOLD Buy
+57.6% avg upside
3 analysts
$14.00
27.31% Upside
 -2.8% ·
MBOT
Microbot Medical
 Feb 10, 2026 BUY Strong Buy
+298.8% avg upside
7 analysts
$5.00
197.68% Upside
 -15.1% ·
INGN
Inogen
 Jan 21, 2026 BUY Buy
+324.5% avg upside
7 analysts
$14.00
141.06% Upside
 -9.6% ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Anderson Schock — Frequently Asked Questions
How accurate are Anderson Schock's stock ratings?
Based on the calls 13Foresight could measure, about 71% of Anderson's ratings were profitable over a one-year hold, with an average return of +17.4% per rating, or +10.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Anderson ranked on 13Foresight?
Anderson Schock is currently ranked #398 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Anderson cover?
Anderson most recently has ratings on VREX, LFMD, XGN, INFU, ANIK, NUTX, CLPT, OBIO, ELMD, OPRX, TCMD, BEAT and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.